Journal of Clinical Pharmacology
Overview
The Journal of Clinical Pharmacology is a peer-reviewed medical journal that focuses on the study of drugs and their effects on human health. It publishes original research articles, reviews, and case reports related to clinical pharmacology, drug development, drug safety, and therapeutic drug monitoring. The journal serves as a valuable resource for healthcare professionals, researchers, and pharmaceutical industry experts seeking to enhance patient care and optimize drug therapy.
Details
Details
Abbr.
J Clin Pharmacol
Publisher
Wiley
Start
1973
End
Continuing
Frequency
Monthly, 1987-
p-ISSN
0091-2700
e-ISSN
1552-4604
Country
United Kingdom
Language
English
Specialty
Pharmacology
Metrics
Metrics
h-index / Ranks: 1919
130
SJR / Ranks: 6135
717
CiteScore / Ranks: 4651
5.30
JIF / Ranks: 3624
2.9
Recent Articles
1.
Lee C, Kwon E, Green F, Kelley C, Pham J, Abulwerdi G, et al.
J Clin Pharmacol
. 2025 Mar;
PMID: 40066584
Dose selection is a critical process within pediatric drug development and dose-ranging studies are integral to establish a reasonable dose. The objective of this analysis was to examine the dose-ranging...
2.
Younis I, Weber E, Nelson C, Qin A, Watkins T, Othman A
J Clin Pharmacol
. 2025 Mar;
PMID: 40052566
Fenofibrate is contraindicated in patients with advanced hepatic fibrosis due to limited clinical data. We evaluated the pharmacokinetics and safety of fenofibrate in participants with mild hepatic impairment (phase 1...
3.
Nakai M, Iwanaga Y, Kanaoka K, Sumita Y, Nishioka Y, Myojin T, et al.
J Clin Pharmacol
. 2025 Mar;
PMID: 40029113
Clinical evidence of oral inotrope use for advanced heart failure (HF) is limited. This study investigated the contemporary use and association of oral inotropes with prognosis in the outpatient treatment...
4.
Chen X, Lin Z
J Clin Pharmacol
. 2025 Mar;
PMID: 40029105
This study presents the first physiologically based pharmacokinetic (PBPK) model for deucravacitinib, a novel oral selective tyrosine kinase 2 (TYK2) inhibitor approved for treating moderate-to-severe plaque psoriasis. Using GastroPlus, we...
5.
Chang Y, Jusko W
J Clin Pharmacol
. 2025 Feb;
PMID: 39982761
This study compares the pharmacokinetics and efficacy of various subcutaneously (SC) dosed insulin analogs, including rapid-acting, intermediate-acting, long-acting, and regular human insulin, using mechanistic pharmacokinetic (PK) and pharmacodynamic (PD) models....
6.
Seazzu M, Cabanilla M
J Clin Pharmacol
. 2025 Feb;
PMID: 39976084
The global rise in extended-spectrum β-lactamase-producing Enterobacterales (ESBL-E) has created significant challenges in the management of severe infections, including bacteremia. Ertapenem, a once-daily carbapenem with high protein-binding affinity (85%-95%), is...
7.
8.
Kharouba M, Aboelezz A, Kung J, Mahmoud S
J Clin Pharmacol
. 2025 Feb;
PMID: 39969140
Levetiracetam is an antiseizure medication (ASM) that has several advantages over other ASMs, such as dose-proportional pharmacokinetics, high bioavailability, and minimal drug interactions. The drug is primarily eliminated through the...
9.
Zhou X, Yang X, Grinshpun B, Taylor A, Strong L, Dasari A, et al.
J Clin Pharmacol
. 2025 Feb;
PMID: 39969131
Fruquintinib is a selective, oral tyrosine kinase inhibitor of all three vascular endothelial growth factor receptors 1, 2, and 3, which is approved for patients with previously treated metastatic colorectal...
10.
Lexnoi T, Boonpeng A, Santimaleeworagun W, Chaisiri K, Dechsanga J, Vattanavanit V, et al.
J Clin Pharmacol
. 2025 Feb;
PMID: 39967294
Pathophysiologic changes in the early and late phases of septic shock affect the pharmacokinetic (PK) parameters, varying dose adjustments may be necessary. This study aimed to create the PK models...